LAUSR

Postexposure prophylaxis (PEP) is a World Health Organisation-endorsed approach to prevent HIV acquisition from a recent sexual exposure by initiating an antiretroviral drug regimen, within 72 h after the exposure, but ideally within 24 h, and continuing for 28 days [1]. Nonhuman primate studies suggest that PEP may reduce the risk of acquiring HIV by around 90% [2], with the efficacy likely to be higher the earlier PEP is initiated after sexual exposure. The current recommended regimen for PEP includes TLD (tenofovir/lamivudine/dolutegravir), the same as the recommended first line regimen for treatment of people with HIV. Countries have policies to provide PEP, but these usually require a clinic visit and PEP use is generally low. We hypothesize that providing easy, local PEP access would have a beneficial effect on HIV incidence which outweighs any negative effects.